Key result
Review outlines key drug interactions between atrial fibrillation therapies and experimental COVID-19 treatments.
Why the study?
Little is known about atrial fibrillation and its optimal management in patients with COVID-19 despite emerging data on cardiovascular disease associations.
What are the pharmacological interactions between cardiovascular drugs used for atrial fibrillation and experimental COVID-19 therapies?
What are the pharmacological interactions between cardiovascular drugs used for atrial fibrillation and experimental COVID-19 therapies?
This review highlights potential pharmacological interactions between atrial fibrillation medications and experimental COVID-19 treatments to guide clinical management.
May guide AF drug selection with experimental COVID-19 therapies; hypothesis-generating pending prospective validation.
Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concerns because of a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known about atrial fibrillation and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in atrial fibrillation management and experimental COVID-19 therapies, based on EU and US summaries of product characteristics.
No takes yet. Share an insight, caveat, or question.
Russo et al. (2020) conducted a review in Atrial Fibrillation and COVID-19. Cardiovascular drugs and experimental COVID-19 therapies was evaluated on Pharmacological interactions. This review describes the pharmacological interactions between cardiovascular drugs commonly used for atrial fibrillation and experimental COVID-19 therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: